CA
Live price temporarily unavailable.
Price history
Cabaletta Bio (CABA) is a Health Care company in the Russell 2000. Latest news and coverage below.
IPO: October 25, 2019 · $11.00 offering · NASDAQ · View IPO details →
Cabaletta Bio net income history (FY2018–FY2025)
Net income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$6.19M | −$18.7M | −$33.8M | −$46.3M | −$54.1M | −$74.7M | −$125.1M | −$172.2M |
| Net income | −$12.2M | −$16.9M | −$33.3M | −$46.3M | −$53.0M | −$67.7M | −$115.9M | −$167.9M |
| EPS (diluted) | −$6.87 | −$4.07 | −$1.44 | −$1.80 | −$1.81 | −$1.65 | −$2.34 | −$2.10 |
| Balance sheet | ||||||||
| Cash and equivalents | $33.0M | $136.2M | $101.4M | $122.2M | $81.6M | $193.2M | $164.0M | $83.0M |
| Total assets | $34.2M | $141.5M | $114.7M | $126.3M | $117.0M | $253.7M | $185.0M | $165.1M |
| Total liabilities | $44.9M | $3.15M | $5.18M | $8.38M | $12.4M | $17.5M | $32.7M | $53.0M |
| Shareholders' equity | −$10.7M | $138.3M | $109.5M | $118.0M | $104.5M | $236.2M | $152.3M | $112.1M |
| Cash flow | ||||||||
| Operating cash flow | −$4.66M | −$16.0M | −$26.8M | −$34.1M | −$46.4M | −$53.5M | −$88.2M | −$131.1M |
| Capital expenditure | — | $693.0K | $635.0K | $1.17M | $2.45M | $687.0K | $2.21M | $1.23M |
| Free cash flow | — | −$16.7M | −$27.4M | −$35.3M | −$48.8M | −$54.2M | −$90.4M | −$132.3M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$33.0M | −$33.8M | −$37.1M | −$45.9M | −$46.6M | −$42.6M | −$44.3M | −$52.0M |
| Net income | −$30.6M | −$32.6M | −$35.9M | −$45.1M | −$44.9M | −$41.9M | −$43.5M | −$51.0M |
| EPS (diluted) | −$0.62 | −$0.65 | −$0.71 | −$0.73 | −$0.44 | −$0.22 | −$0.39 | −$0.34 |
| Balance sheet | ||||||||
| Cash and equivalents | $170.6M | $164.0M | $131.8M | $145.6M | $60.2M | $83.0M | $116.6M | $225.1M |
| Total assets | $204.4M | $185.0M | $165.1M | $224.5M | $189.8M | $165.1M | $148.1M | $256.7M |
| Total liabilities | $30.2M | $32.7M | $43.6M | $46.0M | $50.3M | $53.0M | $44.8M | $46.1M |
| Shareholders' equity | $174.2M | $152.3M | $121.6M | $178.5M | $139.5M | $112.1M | $103.3M | $210.6M |
| Cash flow | ||||||||
| Operating cash flow | −$20.3M | −$23.1M | −$30.8M | −$30.4M | −$34.5M | −$35.3M | −$42.6M | −$41.5M |
| Capital expenditure | $253.0K | $376.0K | $785.0K | $161.0K | $78.0K | $205.0K | $0 | $0 |
| Free cash flow | −$20.6M | −$23.5M | −$31.6M | −$30.6M | −$34.6M | −$35.5M | −$42.6M | −$41.5M |
From Cabaletta Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Cabaletta Bio
- Headquarters
- Philadelphia, Pennsylvania From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with CABA
- BTMD Biote Corp Class a
- BTSG Brightspring Health Services Inc
- BVS Bioventus Class a Inc
- BWAY BrainsWay
- CADL Candel Therapeutics Inc
- CAI Caris Life Sciences
- CAMP CAMP4 THERAPEUTICS
- CAPR Capricor Therapeutics Inc